PEspeaks

May 27, 2015
Emerging technology partnerships in the biopharma space may be provide hope in accelerating patient enrollment, writes Michael Christel.
May 26, 2015
A hot commodity, the FDA’s Rare Pediatric Disease Priority Review Voucher program once again proved its worth, with today’s $245m transaction.
May 26, 2015
Widespread use and abuse of opioid painkillers is prompting efforts to develop new drugs and formulations that resist abuse while providing relief to legitimate patients, writes Jill Wechsler.
May 26, 2015
Increasing the speed and efficiency of clinical trials is an agreed-upon priority. What is less apparent, however, is which approaches have worked which haven't in recent years. Michael Christel reports.
May 25, 2015
The overall impression from the media is that the biotech industry is doing a great job inventing new drugs and treatments and that strong companies are getting the funding they need. But it's not that clear cut, writes Peter Young.
May 25, 2015
The House Energy & Commerce (E&C) Committee unanimously approved the 21st Century Cures legislation last week, but the debate is slated to continue for several months, if not longer. Jill Wechsler reports.
May 21, 2015
After hearing “strong views” on the issue, FDA is expected to release biosimilar-naming guidance later this year.
May 20, 2015
Current clinical trials are regarded as “too slow, too expensive, not reliable, and not designed to answer the important questions,” according to FDA’s new deputy commissioner for medical products &tobacco, Robert Califf.
May 19, 2015
NICE's proposed Innovation Office emerges with a new name. Leela Barham reports.
May 18, 2015
Reflector looks at the revitalized European Union directive on patients’ rights in cross-border healthcare.